Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer

Traynelis, 1994, Current status of intravesical therapy for bladder cancer, Urology annual, 113

Lamm, 1991, Comparison of BCG with other intravesical agents, Urology, 37, 30, 10.1016/0090-4295(91)80136-U

Prout, 1983, Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa, J Urol, 130, 677, 10.1016/S0022-5347(17)51400-7

Akaza, 1987, Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer, Cancer Chemother Pharmacol, 20, S91

Lamm, 1992, Long-term results of intravesical therapy for superficial bladder cancer, The Urology Clinics of North America, 573

Krege, 1996, A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection plus bacillus Calmette-Guérin, J Urol, 156, 962, 10.1016/S0022-5347(01)65673-8

Cookson, 1992, Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy, J Urol, 148, 797, 10.1016/S0022-5347(17)36724-1

Alfthan, 1983, Tigason (etretinate) in prevention of recurrence of superficial bladder tumors: a double-blind clinical trial, Eur Urol, 9, 6, 10.1159/000474033

Vegt, 1995, A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin TICE and bacillus Calmette-Guérin RIVM treatment in Pta-PT1 papillary carcinoma and carcinoma in situ of the bladder, J Urol, 153, 929, 10.1016/S0022-5347(01)67606-7

DeBruyne, 1988, BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer: first results of randomized prospective trial, Urology, 31, 20

Herr, 1988, Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer, J Clin Oncol, 6, 1450, 10.1200/JCO.1988.6.9.1450

Herr, 1991, Transurethral resection and intravesical therapy of superficial bladder tumors, The Urology Clinics of North America, 525

Lamm, 1991, A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional-cell carcinoma of the bladder, N Engl J Med, 325, 1205, 10.1056/NEJM199110243251703

Pagano, 1991, A low-dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective?, J Urol, 146, 32, 10.1016/S0022-5347(17)37707-8

Morales, 1976, Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors, J Urol, 116, 180, 10.1016/S0022-5347(17)58737-6

Herr, 1989, Superficial bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression, J Urol, 141, 22, 10.1016/S0022-5347(17)40575-1

Catalona, 1987, Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer, J Urol, 137, 220, 10.1016/S0022-5347(17)43959-0

Haaff, 1986, Two courses of intravesical bacillus Calmette-Guérin for transitional cell carcinoma of the bladder, J Urol, 136, 820, 10.1016/S0022-5347(17)45091-9

Lamm, 1985, Bacillus Calmette-Guérin immunotherapy for bladder cancer, J Urol, 134, 40, 10.1016/S0022-5347(17)46972-2

Reichert, 1984, Long-term protection in bladder cancer following intralesional immunotherapy, J Urol, 132, 570, 10.1016/S0022-5347(17)49748-5

Badalament, 1987, A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer, J Clin Oncol, 5, 441, 10.1200/JCO.1987.5.3.441

Hudson, 1987, Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective randomized trial, J Urol, 138, 295, 10.1016/S0022-5347(17)43125-9

Lamm, 1995, BCG in perspective: advances in the treatment of superficial bladder cancer, Eur Urol, 27, 2, 10.1159/000475201

Kavoussi, 1988, Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors, J Urol, 139, 935, 10.1016/S0022-5347(17)42722-4

Lamm, 1994, RDA and megadose vitamins effect on tumour recurrence by tumour grade and stage [abstract 23], J Urol, 151, 233

Lamm, 1994, Enhanced natural killer (NK) cell activity with BCG and vitamin treatment [abstract 991], J Urol, 151, 475

Lamm, 1992, Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer, J Urol, 147, 596, 10.1016/S0022-5347(17)37316-0

DeHaven, 1992, Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity, J Urol, 147, 738, 10.1016/S0022-5347(17)37369-X